What an FDA bulk-substance safety warning means

The FDA keeps lists of bulk drug substances nominated for use in compounding, and it periodically publishes findings on the ones it believes may present significant safety risks. Several familiar research peptides sit on these lists, including BPC-157, TB-500, and several of the GHRP-family growth hormone secretagogues.

A place on that list generally means at least one of the following. Little or no human exposure data was identified. Adverse events appear in published or reported literature. Or there are impurity and immunogenicity concerns tied to how these substances get manufactured outside a standard pharmaceutical pipeline.

A listing like this is worth taking seriously. The FDA looked at the available safety data for the substance and concluded it falls short of what would justify compounding it for human use. That sits in a more serious category than a compound nobody has studied yet. It stops short of a recall, and a given batch may test clean, yet the agency's own read of the evidence is already on the record.

The flag appears high on every affected compound page, where it changes how the rest of the entry should be weighed.